Sun Pharmaceutical Industries
Acme Plaza
Andheri Kurla Road
Andheri (East)
Mumbai
400 059
Tel: 91-22-821-12-88
Fax: 91-22-821-20-10
Website: http://www.sunpharma.com/
Email: corpcomm@sunpharma.com
232 articles about Sun Pharmaceutical Industries
-
Sun Pharma Introduces Access Program for Patients Prescribed XELPROS in the U.S.
7/17/2019
XELPROS™ 0.005%, the only FDA-approved Benzalkonium chloride-free formulation of latanaprost, was recently launched by Sun Pharma for the treatment of Glaucoma or Ocular Hypertension
-
Sun Pharma Launches Ezallor Sprinkle (Rosuvastatin) in the U.S. for People Who Have Difficulty Swallowing
7/15/2019
Sun Pharmaceutical Industries Ltd. announced the U.S. launch of Ezallor Sprinkle™ capsules for the treatment of three types of elevated lipid disorders in people who have difficulty swallowing, a problem that is estimated to affect approximately 30-35% of long-term care residents.
-
Sun Pharma Announces Late-Breaking Phase 2 Data Showing Potential of ILUMYA™ (tildrakizumab-asmn) to Improve Joint and Skin Symptoms of Psoriatic Arthritis
6/14/2019
Over 71% of Patients Treated with ILUMYA™ Achieved ACR20 Response After 24 Weeks, with Significant Improvement as Early as 8 Weeks MUMB
-
Sun Pharma Launches Ready-to-Infuse INFUGEM in the U.S.
4/8/2019
Use of ready-to-infuse bags eliminates steps in the complex chemotherapy preparation process, reducing exposure and mitigating inherent provider and patient safety risks
-
Sun Pharmaceutical Industries Inc. Announces Plans to Present 19 Data Abstracts on ILUMYA™ for Moderate-to-Severe Plaque Psoriasis at American Academy of Dermatology 2019 Annual Meeting
2/27/2019
Sun Pharmaceutical Industries Inc., USA (SPII) today announced that it plans to present 19 abstracts featuring data on ILUMYA™ (tildrakizumab-asmn), a prescription medicine used to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic or phototherapy, at the 77th Annual Meeting of the American Academy of Dermatology (AAD) from March 1 – 5 in Washington, DC.
-
Ferring Pharmaceuticals adds two products to its robust reproductive health portfolio in the U.S.
1/14/2019
Ferring acquired exclusive U.S. commercialization rights for generic Ganirelix Acetate Injection for the prevention of premature ovulation in women undergoing fertility treatment
-
Sun Pharmaceutical Industries, Inc. Issues Voluntary Nationwide Recall of Vecuronium Bromide for Injection Due to the Presence of Particulate Matter Identified as Glass
1/8/2019
The Vecuronium Bromide for Injection has been found to contain particulate matter identified as glass.
-
It apparently began with a 2016 federal lawsuit. At that time, 20 state attorneys general filed a federal lawsuit alleging that six generic drug makers artificially inflated and manipulated prices for an antibiotic and an oral diabetes drug. The goal was to reduce competition.
-
Sun Pharma Announces the Availability of ILUMYA™ (tildrakizumab-asmn) in the United States for the Treatment of Moderate-to-Severe Plaque Psoriasis
10/23/2018
New Insights on the Cost-Effectiveness of ILUMYA™ Presented Today at the Academy of Managed Care Pharmacy Nexus 2018 Meeting
-
Part of the Trump Administration and the U.S. Food and Drug Administration (FDA)’s strategy to push down drug prices is to develop ways to increase competition. As such, the agency launched a Drug Competition Action Plan that has several components.
-
Forbes came out with its ranking of the World’s Best Employers 2018, with a number of global biopharmaceutical companies ranked high on the list. Here’s the top 10 in that category.
-
Sun Pharma and SPARC Announce US FDA Approval of XELPROS™ to Treat Open-angle Glaucoma or Ocular Hypertension
9/14/2018
XELPROSTM (latanoprost ophthalmic emulsion) 0.005% for topical ophthalmic use is the first and only benzalkonium chloride-free (BAK-free) form of latanoprost
-
Sun Pharma Announces U.S. FDA Approval of CEQUA™ to Treat Dry Eye Disease
8/16/2018
CEQUA (cyclosporine ophthalmic solution) 0.09% for topical ophthalmic use is the first and only dry eye treatment to combine cyclosporine A with nanomicellar technology
-
Shares of Sun Pharmaceuticals have climbed more than 3 percent this morning after the U.S. Food and Drug Administration approved its dry eye treatment Cequa (cyclosporine ophthalmic solution) 0.09 percent.
-
Sun Pharma Launches Novel Drug Kapspargo Sprinkle™ in USA
8/6/2018
First USFDA approved, extended-release sprinkle formulation of metoprolol succinate indicated for treatment of patients with Hypertension, Angina Pectoris and Heart Failure
-
Cipher Pharmaceuticals Announces Amended Distribution and Supply Agreement for Absorica
7/30/2018
New portfolio royalty extends through December 2024
-
Last year, Novartis’ multiple sclerosis drug Gilenya generated more than $3 billion in revenue, with a little more than half of that coming from sales in the United States. As the drug faces patent loss in the future, Novartis is fighting to preserve that revenue driver with multiple lawsuits.
-
Sun Pharma received approval from the U.S. Food and Drug Administration (FDA) for Yonsa (abiraterone acetate) to treat metastatic castration-resistant prostate cancer (mCRPC). Sun will launch the drug in the U.S. via a licensing deal with Churchill Pharmaceuticals, the original developer of the d...
-
Sun Pharma Announces USFDA Approval of YONSA® (abiraterone acetate) To Treat Metastatic Castration-Resistant Prostate Cancer In Combination With Methylprednisolone
5/23/2018
Sun Pharmaceutical Industries Ltd. and Churchill Pharmaceuticals, LLC. today announced that one of Sun Pharma’s wholly owned subsidiary companies has received approval from the U.S. Food and Drug Administration (FDA) for YONSA® (abiraterone acetate).
-
Sun Pharma Announces U.S. FDA Approval of ILUMYA™ (tildrakizumab-asmn) for the Treatment of Moderate-to-Severe Plaque Psoriasis
3/21/2018
Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and includes its subsidiaries and/or associate companies) today announced that the U.S. Food and Drug Administration (FDA) has approved ILUMYA™ (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.